The overhaul of America’s vaccine advisory system has delayed routine recommendations and widened the gap between CDC guidance, medical advice and insurance coverage.
Federal vaccine policy has been left in disarray after Health Secretary Robert F. Kennedy Jr.’s overhaul of the advisory system, with new recommendations stalled, routine updates delayed and doctors’ groups stepping in to fill the gap. What was once a largely predictable process, in which the Centres for Disease Control and Prevention reviewed evidence in public and quickly translated it into national guidance, has become slower, less transparent and, in some cases, paralysed. According to The Associated Press reporting published by the Boston Globe, that has already affected guidance on a new flu shot, updated COVID vaccines and childhood immunisation schedules.
For decades, the Advisory Committee on Immunization Practices served as the main bridge between vaccine data and public policy. The panel met in public, weighed evidence, heard from medical specialists and voted on recommendations that the CDC director almost always adopted. Those decisions shaped what doctors advised and what insurers paid for. Kennedy dismissed the committee and replaced it with a group that included several prominent anti-vaccine voices, prompting lawsuits from the American Academy of Pediatrics and other medical groups. A federal judge later said Kennedy was likely to have violated procedures and temporarily blocked further meetings, as well as his decision to reduce the number of vaccines recommended for children, according to court reporting cited in the AP story and related coverage from the American Academy of Pediatrics and Ars Technica.
The effect has been especially visible this year in recommendations that would normally have been routine. The CDC has not issued formal guidance on mFlusiva, a newly approved flu vaccine made with mRNA technology, even though the Food and Drug Administration cleared it for people aged 50 to 64 after studies in older adults. Instead, the agency quietly said this month it would keep last year’s flu vaccine endorsements because of “legal uncertainties and inquiries”, leaving the shot off the list of vaccines recommended to the public this autumn. Medical societies, however, continue to include it as an option. The same split has emerged on respiratory syncytial virus protection in pregnancy: while the CDC’s guidance still limits use to a September-to-January window in most of the United States, medical groups have extended their advice into early March to better match the virus’s sometimes longer season, according to the AP and the insurance trade group America’s Health Insurance Plans.
Other programmes have also been caught in the crossfire. The government delayed confirming whether updated COVID-19 shots would be covered under the Vaccines for Children programme, which pays for immunisations for children without insurance, until officials said only this week that orders could be placed. Questions around the human papillomavirus vaccine have also been unsettled. In 2024, ACIP had begun reviewing whether one dose might be enough in some cases, particularly for girls, but that work was interrupted when Kennedy removed the committee. He later ordered a one-dose recommendation on his own as part of a broader contraction of the childhood schedule, a move that was suspended by the court order. The American Academy of Pediatrics is now weighing whether to revise its own HPV guidance, with a decision possible later this year, according to the AP report and a statement from the organisation.
The wider problem, public health experts say, is not simply that recommendations have changed, but that trust in the system has been damaged. Jason Schwartz, a Yale University health policy researcher, told the AP that even when credible evidence points towards a policy shift, there is no longer an obvious mechanism to turn it into formal guidance. Chris Regal of America’s Health Insurance Plans said in a webinar that vaccine policy needs to evolve, but the process must remain workable for doctors, insurers and families. Democratic governors have warned that proposed changes to federal vaccine categories would add confusion and complexity, while Angela Botticella of the Governors Public Health Alliance said the burden of any outbreak driven by that confusion would fall on states and residents. For now, the result is a patchwork in which official CDC guidance, medical society recommendations and insurer coverage decisions no longer line up as they once did.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
